Related Experiment Video
Updated: Jun 6, 2025
Author Spotlight: A Multi-Depth Porcine Model for Comprehensive Study of Burn Injuries and Healing Processes
Published on: February 23, 2024
Nonsteroidal Anti-Inflammatory Drugs Decrease Coagulopathy Incidence in Severe Burn Patients
Lyndon Huang1, Kassandra Corona1, Kendall Wermine1
1School of Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA.
Abstract:
The study investigated the impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on burn-induced coagulopathy in severely burned patients. Patients with a greater than 20% TBSA were identified in the TriNetX research network and categorized into receiving or not receiving NSAIDs in the first week after the burn. The statistical significance of the rate of burn-induced coagulopathy, mortality and sepsis in the week following injury was analysed. We observed 837 severely burned patients taking NSAIDS during the week following the burn and 1036 patients without. After matching for age, gender and race, the risk of burn-induced coagulopathy significantly decreased (p < 0.0001) in patients taking NSAIDs (17.7%) compared to those without (32.3%). Patients taking NSAIDs were also less likely to develop sepsis (p < 0.01) and thrombocytopenia (p < 0.001) or die the week following injury (p < 0.0001). In conclusion, the early protective effects of NSAIDs at reducing the risk of coagulopathy as well as sepsis and mortality occur during the acute phase of burns.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) significantly reduced coagulopathy, sepsis, and mortality in severely burned patients. Early NSAID use offers protective benefits during the acute phase of burn injury.
Area of Science:
- Trauma Surgery
- Pharmacology
- Critical Care Medicine
Background:
- Burn-induced coagulopathy is a severe complication impacting patient outcomes.
- Early intervention strategies are crucial for managing severe burn injuries.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) have potential anti-inflammatory and analgesic properties.
Purpose of the Study:
- To investigate the impact of early nonsteroidal anti-inflammatory drug (NSAID) administration on burn-induced coagulopathy.
- To assess the effect of NSAIDs on mortality and sepsis development in severely burned patients.
- To determine the protective role of NSAIDs during the acute phase of severe burns.
Main Methods:
- Retrospective cohort study using the TriNetX research network.
- Identification of severely burned patients (TBSA > 20%) receiving NSAIDs within the first week post-burn.
- Statistical analysis comparing coagulopathy, sepsis, and mortality rates between NSAID and non-NSAID groups after matching.
Main Results:
- NSAID use was associated with a significant reduction in burn-induced coagulopathy (17.7% vs. 32.3%, p < 0.0001).
- Patients receiving NSAIDs showed significantly lower rates of sepsis (p < 0.01) and mortality (p < 0.0001).
- NSAID group also demonstrated a significant decrease in thrombocytopenia (p < 0.001).
Conclusions:
- Early administration of NSAIDs demonstrates significant protective effects in severely burned patients.
- NSAIDs reduce the risk of burn-induced coagulopathy, sepsis, and mortality in the acute phase.
- NSAIDs represent a potential therapeutic option for improving outcomes in severe burn management.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22Burn Injuries
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:05Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...